The BRIGHT trial is a phase 1, open-label, dose-escalation study for CRISPR/Cas13-RNA targeting therapy for the treatment of ...

In a 2022 study, Sodhi’s group identified ANGPTL4 as a potential culprit in nonresponse to anti-VEGF drugs, which are ...

Opens in a new tab or window A novel gene therapy (ABBV-RGX-314) was well tolerated and reduced treatment burden in patients with bilateral neovascular age-related macular degeneration (AMD ...

Practice-changing studies in dry age-related macular degeneration (AMD) and promising new directions in wet AMD, presented at ...

Reduced well-being and loss of productivity were contributors to the high economic burden in patients with late-stage age-related macular degeneration (AMD) living in the US, Germany, and Bulgaria.

Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...

Opens in a new tab or window CHICAGO -- An artificial intelligence (AI)-based study of home monitoring for neovascular age-related macular degeneration (AMD) suggested a potential annual savings ...

LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024- Appointed Jason Mitchell as chief ...

The approach to managing neovascular or wet AMD varies based on the stage and type of the condition. Incorporating a nutritious diet, engaging in regular physical activity, and quitting smoking ...

Worldwide, age-related macular degeneration (AMD) is the leading cause of severe vision loss in people aged 50 or older.